PubMedCrossRef 22. Ahlegren G, Pedersen K, Lundberg S, et al.: Regressive changes and neuroendocrine differentiation in prostate cancer
after neoadjuvant hormonal treatment. Prostate 2000, 42: 274–279.CrossRef 23. Hvamstad T, Jordal A, Hekmat N, et al.: Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003, 44: 215–221.PubMedCrossRef 24. Mosca A, Dogliotti L, Berruti A, et al.: Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: prostate cancer. Dig Liver Dis 2004, 36: 60-S67.CrossRef 25. Isshiki S, Akakura K, Komiya A, et al.: Chromogranin A concentration as a serum marker HSP inhibitor to predict prognosis after endocrine GSK1904529A purchase therapy for prostate cancer. J Urol 2002, 167: 512–515.PubMedCrossRef 26. Ranno S, Motta M, Rampello E, et al.: The chromogranin-A (CgA) in prostate cancer. Arch Gerontol Geriatr 2006, 43: 117–26.PubMedCrossRef 27. Kimura N, Hoshi S, Takahashi M, et al.: Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997, 157: 565–7.PubMedCrossRef 28. Hirano D, Okada Y, Minei S, et al.: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004, 45: 586–592.PubMedCrossRef 29. Grimaldi F, Valotto C, Barbina
G, et al.: The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer. Int J Biol Markers 2006, 21: 229–34.PubMed 30. Aprikian AG, Cordon-Cardo C, Fair W, et al.: Characterization of neuroendocrine differentiation
in human benign prostate and prostate adenocarcinoma. Cancer 1993, 71: 3952–65.PubMedCrossRef 31. Pruneti G, Galli S, Rossi RS, et al.: Chromogranin A and B secretogranin II in prostatic adenocarcinomas: neuroendocrine Urease expression in patients untreated and treated with androgen deprivation therapy. Prostate 1998, 34: 113–20.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions MA made substantial contributions to the conception, design and coordination of the study as well as the preparation of the final version of the manuscript. AM, GP and CVI were involved in the process of patient selection and in the data collection. PDC was responsible for enrolling patients. RB and AB participated in data collection. GC performed the tests in the laboratory. IS carried out the data analyses. MG participated in the coordination of the final version of the manuscript. All authors have read and approved the final manuscript.”
“Background selleck screening library Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms occurring throughout the entire region of the gastrointestinal tract and are considered to originate from intestitial cells of Cajal, the pacemaker cells of the gut [1].